Ge Healthcare Technologies Inc - GEHC STOCK NEWS

GE HealthCare Technologies Inc. (GEHC) announced the pricing of a secondary underwritten public offering of 13,000,000 shares of its common stock at $82.25 per share. General Electric Company (GE) is expected to exchange the GEHC shares for indebtedness held by Morgan Stanley. The offering, led by top financial institutions, is expected to close on February 21, 2024.

GE HealthCare Technologies Inc. (Nasdaq: GEHC) has announced a secondary underwritten public offering of 13,000,000 shares of its common stock. The company will not receive any proceeds from the sale, as General Electric Company is expected to exchange the shares for indebtedness held by Morgan Stanley. The offering includes an option for underwriters to purchase additional shares, with major financial institutions serving as lead book-running managers.

GE HealthCare (Nasdaq: GEHC) announces CFO Jay Saccaro's participation in key investor conferences, providing access to the events for stakeholders.

GE HealthCare (GEHC) and MedQuest Associates announced a three-year collaboration to optimize multi-site outpatient imaging networks for success. The partnership aims to provide innovative technologies from GE HealthCare and the infrastructure and resources from MedQuest to deliver excellence in patient care. MedQuest will leverage GE HealthCare's AI-enabled digital capabilities to enhance care delivery and product line development in outpatient imaging. The collaboration is expected to boost operational efficiency, expand access, and improve patient outcomes.

GE HealthCare (Nasdaq: GEHC) reported strong financial performance for the fourth quarter and full year 2023, with revenue growth of 5% and 7% year-over-year respectively. The company also provided 2024 financial guidance, demonstrating progress toward medium-term financial targets. However, net income margin and adjusted EBIT margin saw declines compared to the prior year. Cash flow from operating activities and free cash flow also experienced slight decreases. Despite these declines, the company invested over $1 billion in R&D for future growth and made significant strides in innovation and market position through strategic acquisitions.

GE HealthCare (Nasdaq: GEHC) reported strong financial performance in the fourth quarter and full year of 2023. Revenue growth was 5% year-over-year in Q4 and 7% for the full year. Net income margin was 7.7% in Q4 and 8% for the full year. Adjusted EBIT margin was 16.1% in Q4 and 15.1% for the full year. Cash flow from operating activities was $1.1 billion in Q4 and $2.1 billion for the full year. The company provided 2024 financial guidance, demonstrating progress toward medium-term financial targets.

GE HealthCare has received FDA clearance for an expanded indication for Novii+ maternal and fetal monitoring solution for pregnant patients ≥34 weeks. The Novii+ noninvasively measures and displays fetal heart rate, maternal heart rate, and uterine activity, providing patient comfort and mobility in the hospital. The wireless design enables mobility and freedom for mothers, and studies have shown that it may help decrease the length of labor. Novii+ is an expanded indication from the Novii Maternal and Fetal Monitoring Solution that utilizes an updated algorithm to improve reliability and accuracy. It can be used for both antepartum and intrapartum pregnant patients 34 weeks and greater, which extends usage before the previously defined use of 37 weeks and greater of pregnancy. The expanded indication is based on data submitted to the FDA to determine Novii+ Wireless Patch Solution’s equivalence to doppler fetal heart rate, tocodynamometer uterine activity, and pulse oximetry maternal heart rate devices for preterm patients (≥34 weeks) in terms of accuracy and reliability. It is a first-of-its-kind patch-based antepartum and intrapartum monitoring solution for preterm patients (≥34 weeks). The Novii+ Wireless Patch Solution will be available to customers in the United States later this year.

GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. The new platform maintains high signal fidelity, reduces environmental noise, and offers advanced analytics for the diagnosis and treatment of cardiac arrhythmias. The prevalence of AFib is projected to affect millions globally, making the need for accurate and efficient recording systems crucial. The new Prucka 3 system is designed to address these needs and enable path to new technologies in the EP lab.

GE HealthCare (Nasdaq: GEHC) will announce its Q4 and full year 2023 financial results on February 6, 2024. A live webcast and conference call will be hosted by the management team at 8:30 a.m. Eastern Time. The webcast replay and financial information will be available on the GE HealthCare Investor Relations website.